[CAS NO. 1030203-81-6] HS38
PRODUCTS SPECIFICATIONS [1030203-81-6]
DESCRIPTION [1030203-81-6]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 349.80 |
| Molecular Formula | C14H12ClN5O2S |
| SMILES | CC(SC1=NC(N(C2=CC=CC(Cl)=C2)N=C3)=C3C(N1)=O)C(N)=O |
Summary
HS38 is a potent, selective, and ATP-competitive inhibitor of death-associated protein kinase 1 (DAPK1) and zipper-interacting protein kinase (ZIPK, also called DAPK3) , with K d s of 300 nM and 280 nM, respectively. HS38 is also a PIM3 inhibitor with an IC 50 of 200 nM. HS38 can be used for the research of smooth muscle related disorders [1] .
IC50 & Target
Kd: 300 nM (DAPK1), 79 nM (DAPK2), 280 nM (ZIPK), IC50: 200 nM (DAPK1), 200 nM (PIM3) [1]
In Vitro
HS38 displays high affinity toward DAPK2, with a K
d
of 79 nM. DAPK2 is not implicated in smooth muscle contractility
[1]
.
HS38 significantly reduces relative RLC20 phosphorylation in both the basal and sphingosine 1-phosphate (S1P) activated states in human aortic SM cells
[1]
.
HS38 reduces contractile forces generated by intact mouse aorta in aortic tissue
[1]
.
HS38 reduces the contractile force, RLC20 phosphorylation, and MYPT1 phosphorylation in Ca
2+
-sensitized rabbit ileum
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis [1]
| Cell Line: | CA-VSMCs |
| Concentration: | 10 µM |
| Incubation Time: | 40 minutes |
| Result: | Reduced relative RLC20 phosphorylation in both the basal and S1P activated states. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 7.14 mg/mL ( 20.41 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.8588 mL | 14.2939 mL | 28.5878 mL |
| 5 mM | 0.5718 mL | 2.8588 mL | 5.7176 mL |
| 10 mM | 0.2859 mL | 1.4294 mL | 2.8588 mL |